Looking at the filing, I can confirm this is a Form 10-Q for Absci Corporation, trading as NASDAQ:ABSI, for the quarterly period ended June 30, 2026. The filing contains substantive disclosure content well above 150 words.

Absci Corporation (NASDAQ:ABSI), a drug creation company based in Vancouver, Washington, filed its Form 10-Q for the quarterly period ended June 30, 2026, with the U.S. Securities and Exchange Commission on August 11, 2026.

Key Highlights

  • Shares outstanding: 171,614,010 shares of $0.0001 par value common stock were outstanding as of July 31, 2026.
  • Reporting period: The quarterly period covered is April 1, 2026 through June 30, 2026.
  • Filer status: Absci Corp is classified as a non-accelerated filer, smaller reporting company, and emerging growth company.
  • Platform focus: The company operates an Integrated Drug Creation platform used for identifying, designing, and advancing product candidates.
  • Continued losses expected: According to the filing, the company "has incurred significant losses since inception" and expects to incur losses in the future.
  • Capital needs disclosed: The filing states the company "will need to raise additional capital to fund our operations, preclinical and clinical development" and expansion of its platform.

Absci Corp's Q2 2026 Filing: Platform Strategy, Loss History, and Capital Requirements

Absci Corporation, incorporated in Delaware and headquartered at 18105 SE Mill Plain Blvd, Vancouver, WA 98683, filed its quarterly report covering the period ended June 30, 2026. The company describes itself as operating an Integrated Drug Creation platform, which it uses to identify, design, and advance biologic drug candidates both through internally developed programs and through partnerships with external parties. As of July 31, 2026, the company had 171,614,010 shares of common stock outstanding at a par value of $0.0001 per share.

According to the filing, Absci Corp has incurred significant losses since inception and expects those losses to continue. The company disclosed that it "will need to raise additional capital to fund our operations, preclinical and clinical development of our internally developed programs, and to expand the capabilities of our Integrated Drug Creation platform." The filing further states that if such capital cannot be raised "on terms acceptable to us or at all," the company may not be able to continue developing its programs or compete effectively with its platform, which it characterized as potentially harmful to its "business, operations, and financial condition."

The filing identifies the markets in which Absci operates as "highly competitive," and notes that the company's commercial success depends on the technological capabilities of its Integrated Drug Creation platform as well as the advancement of its internally developed programs. Biologic drug development is described as "inherently uncertain," and the company cautioned that even successful platform performance may not result in product candidates reaching regulatory approval or commercialization. The company also noted reliance on third parties to conduct preclinical studies and clinical trials, and dependence on a limited number of suppliers for laboratory equipment and materials.

What Was Disclosed

Absci Corporation submitted a Form 10-Q for the quarter ended June 30, 2026, disclosing its filer status, share count as of July 31, 2026, ongoing operating losses, capital needs, and a detailed summary of business and operational risk factors related to its Integrated Drug Creation platform.